ArticleCancers2026
18β-Glycyrrhetinic Acid Exerts Subgroup-Specific Antitumor Activity and Enhances Radiosensitivity in Medulloblastoma.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) is a cornerstone of medulloblastoma (MB) treatment, but its efficacy may be limited by intrinsic or acquired radioresistance, while radiation-related late effects remain a major concern in pediatric patients. 18β-Glycyrrhetinic acid (18β-GA), a bioactive triterpenoid derived from
methodsDAOY cells, used as an SHH-associated, TP53-mutant model, and D283 cells, commonly considered a Group 3/Group 4-associated model, were treated with 18β-GA (2.5-5 μM), γ-radiation (2-4 Gy), or their combination. Cell viability, clonogenic survival and migration were assessed. Apoptosis was evaluated by caspase-3/7 activity and cleaved caspase-3 expression. Modulation of AMPK/NF-κB and SHH signaling was examined by immunoblotting and RT-qPCR.
results18β-GA reduced cell viability in a dose- and time-dependent manner and significantly reduced wound closure in DAOY cells and migratory capacity in D283 cells. D283 cells showed greater apoptotic sensitivity, accompanied by increased total and phosphorylated AMPK and reduced NF-κB p65 expression. In DAOY cells, 18β-GA reduced the expression of SHH-associated transcriptional markers, including GLI1, SOX2, CCND1, and MYC. Most importantly, 18β-GA significantly enhanced radiation response in both cell lines, producing greater reductions in viability and clonogenic survival than irradiation alone (
conclusions18β-GA exerts antitumor activity in biologically distinct MB models through differential modulation of SHH and AMPK/NF-κB signaling, while converging on enhanced apoptotic susceptibility and a profound loss of clonogenic survival after irradiation. These findings provide a strong rationale for further preclinical evaluation of 18β-GA as a potential radiosensitizing adjuvant in MB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.